Menu

Lilly maintains M&A hot streak with $2.3B deal for next-gen JAK inhibitor biotech Ajax

Article |

MicroMEL31l 24d ago
Lilly maintains M&A hot streak with $2.3B deal for next-gen JAK inhibitor biotech Ajax

Eli Lilly's run of near-weekly acquisitions still shows no sign of...

Comments (0)

Newest

No comments yet.